The positive Phase 2 data for MZE829 represents a major clinical validation for Maze’s platform and de-risks the AMKD program ahead of pivotal trials. With a cash runway into 2028 and upcoming Phase 2 initiations for MZE782, the company is well-positioned for value inflection. Traders should monitor the upcoming conference call for details on pivotal trial design and timelines.
Price Chart
Executive Summary
Maze Therapeutics reported positive Phase 2 HORIZON trial data for MZE829 in APOL1-mediated kidney disease (AMKD), showing a 35.6% mean reduction in proteinuria, supporting advancement to a pivotal program. The company also announced a strong balance sheet with $360.0 million in cash, funding operations into 2028, despite a net loss of $131.1 million in 2025 due to increased R&D and G&A expenses.
Key Financial Metrics
Key Facts
- Positive topline data from Phase 2 HORIZON trial: MZE829 achieved 35.6% mean reduction in uACR in broad AMKD patients, with 50% achieving >30% reduction.
- In severe FSGS patients, MZE829 showed a 61.8% mean reduction in uACR.
- No serious or severe treatment-related adverse events observed.
- Maze plans to advance MZE829 into a pivotal program and initiate two Phase 2 trials for MZE782 in PKU and CKD in 2026.
- Cash, cash equivalents, and marketable securities totaled $360.0 million as of December 31, 2025, up from $196.8 million in 2024.
- Net loss for 2025 was $131.1 million vs. net income of $52.2 million in 2024, primarily due to higher R&D and G&A expenses and absence of $167.5M license revenue from Shionogi upfront payment.
- Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors.
Financial Impact
Increased R&D and G&A spending by $24.9M and $8.0M YoY respectively; offset by no recurring upfront license revenue, leading to a $183.3M swing from 2024 net income to 2025 net loss. However, strong cash position of $360.0M supports multi-year runway.
Risk Factors
- Clinical development risk: Pivotal trials for MZE829 will require significant investment and regulatory scrutiny.
- Dilution risk: Future capital raises may be necessary beyond 2028, depending on development pace.
- Competition: Emerging therapies in AMKD or PKU could impact market potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262077 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 4, 2026 27d ago | Insider Cluster | $26.37 $24.23 | ▼ −8.12% | ▼ −7.00% | $26.69 (+1.20%) |
Sep 3, 2026 29d ago | Insider Cluster | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 2, 2026 29d ago | 144 | $25.87 $24.60 | ▼ −4.91% | ▼ −3.76% | $26.69 (+3.16%) |
Sep 1, 2026 4w ago | 144 | $26.72 $24.82 | ▼ −7.11% | ▼ −6.15% | $26.69 (−0.12%) |
Aug 17, 2026 6w ago | 3 | $29.13 $30.42 | ▲ +4.43% | ▲ +4.63% | $26.69 (−8.38%) |
Aug 11, 2026 7w ago | Press Release | $27.53 $29.75 | ▲ +8.06% | ▲ +8.51% | $26.69 (−3.06%) |
Aug 7, 2026 8w ago | Institutional Cluster | $28.65 $27.18 | ▼ −5.13% | ▼ −5.53% | $26.69 (−6.85%) |
Aug 5, 2026 8w ago | Insider Cluster | $27.81 $27.53 | ▼ −1.01% | ▼ −1.36% | $26.69 (−4.04%) |
Jul 2, 2026 13w ago | Insider Cluster | $31.26 $32.42 | ▲ +3.71% | ▲ +2.78% | $26.69 (−14.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access